CLMT vs VRTX · rev $4.19B vs P/E 30, rev $12.00B
Calumet Specialty Products Partners (CLMT) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Calumet Specialty Products Partners (CLMT) is a specialty chemicals company listed on NASDAQ.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported CLMT revenue for 2024-12-31 was $4.19B. Net income was -$222.0M. Revenue was up 0.2% from 2023-12-31 to 2024-12-31. CLMT currently screens at market cap $2.89B.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
CLMT currently screens at market cap $2.89B. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the CLMT and VRTX stock pages for the full models.
Not investment advice.